155 related articles for article (PubMed ID: 33735560)
41. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma.
Peng Y; Greenland NY; Lang UE; Stohr BA
Pathol Res Pract; 2022 Apr; 232():153831. PubMed ID: 35287088
[TBL] [Abstract][Full Text] [Related]
42. B-MYB-p53-related relevant regulator for the progression of clear cell renal cell carcinoma.
Nientiedt M; Müller K; Nitschke K; Erben P; Steidler A; Porubsky S; Popovic ZV; Waldbillig F; Mühlbauer J; Kriegmair MC
J Cancer Res Clin Oncol; 2021 Jan; 147(1):129-138. PubMed ID: 32951068
[TBL] [Abstract][Full Text] [Related]
43. The Prognostic Significance of Protein Expression of CASZ1 in Clear Cell Renal Cell Carcinoma.
Kim B; Jung M; Moon KC
Dis Markers; 2019; 2019():1342161. PubMed ID: 31481981
[TBL] [Abstract][Full Text] [Related]
44. Prognostic significance of platelet-derived growth factor receptor-β expression in localized clear cell renal cell carcinoma.
Shim M; Song C; Park S; Choi SK; Cho YM; Kim CS; Ahn H
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2213-20. PubMed ID: 26215891
[TBL] [Abstract][Full Text] [Related]
45. Expression pattern of autophagy-related markers in non-metastatic clear cell renal cell carcinoma: association with disease recurrence following radical nephrectomy.
Nishikawa M; Miyake H; Liu B; Fujisawa M
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1585-91. PubMed ID: 25638048
[TBL] [Abstract][Full Text] [Related]
46. LIM and SH3 domain protein 1 (LASP-1) overexpression was associated with aggressive phenotype and poor prognosis in clear cell renal cell cancer.
Yang F; Zhou X; Du S; Zhao Y; Ren W; Deng Q; Wang F; Yuan J
PLoS One; 2014; 9(6):e100557. PubMed ID: 24955835
[TBL] [Abstract][Full Text] [Related]
47. RALY RNA binding protein-like reduced expression is associated with poor prognosis in clear cell renal cell carcinoma.
Cui ZW; Xia Y; Ye YW; Jiang ZM; Wang YD; Wu JT; Sun L; Zhao J; Fa PP; Sun XJ; Gui YT; Cai ZM
Asian Pac J Cancer Prev; 2012; 13(7):3403-8. PubMed ID: 22994768
[TBL] [Abstract][Full Text] [Related]
48.
Lin W; Chen X; Chen T; Liu J; Ye Y; Chen L; Qiu X; Chia-Hsien Cheng J; Zhang L; Wu J; Qiu S
DNA Cell Biol; 2020 Jun; 39(6):1000-1011. PubMed ID: 32282241
[TBL] [Abstract][Full Text] [Related]
49. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
[TBL] [Abstract][Full Text] [Related]
50. MiR-429 is linked to metastasis and poor prognosis in renal cell carcinoma by affecting epithelial-mesenchymal transition.
Machackova T; Mlcochova H; Stanik M; Dolezel J; Fedorko M; Pacik D; Poprach A; Svoboda M; Slaby O
Tumour Biol; 2016 Nov; 37(11):14653-14658. PubMed ID: 27619681
[TBL] [Abstract][Full Text] [Related]
51. Genetic profile and immunohistochemical study of clear cell renal carcinoma: Pathological-anatomical correlation and prognosis.
Diez-Calzadilla NA; Noguera Salvá R; Soriano Sarrió P; Martínez-Jabaloyas JM
Cancer Treat Res Commun; 2021; 27():100374. PubMed ID: 33932757
[TBL] [Abstract][Full Text] [Related]
52. Expression pattern and regulatory effect of lysine-specific demethylase 2A gene in clear cell renal cell carcinoma.
Wang J; Li T; Li X; Zhang Y; Wang X
BMC Urol; 2021 Aug; 21(1):108. PubMed ID: 34391411
[TBL] [Abstract][Full Text] [Related]
53. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.
Kruck S; Merseburger AS; Hennenlotter J; Scharpf M; Eyrich C; Amend B; Sievert KD; Stenzl A; Bedke J
BJU Int; 2012 May; 109(10):1565-70. PubMed ID: 21981759
[TBL] [Abstract][Full Text] [Related]
54. FSIP2 can serve as a predictive biomarker for Clear Cell Renal Cell Carcinoma prognosis.
Zhang Y; Zhu X; Qiao X; Sun L; Tian Y; Yang Y; Zhao Y; Liu C
Int J Med Sci; 2020; 17(17):2819-2825. PubMed ID: 33162809
[No Abstract] [Full Text] [Related]
55. Elevated expression of IFN-inducible CXCR3 ligands predicts poor prognosis in patients with non-metastatic clear-cell renal cell carcinoma.
Liu W; Liu Y; Fu Q; Zhou L; Chang Y; Xu L; Zhang W; Xu J
Oncotarget; 2016 Mar; 7(12):13976-83. PubMed ID: 26910919
[TBL] [Abstract][Full Text] [Related]
56. Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma.
Nagao K; Shinohara N; Smit F; de Weijert M; Jannink S; Owada Y; Mulders P; Oosterwijk E; Matsuyama H
BMC Cancer; 2018 Nov; 18(1):1114. PubMed ID: 30442117
[TBL] [Abstract][Full Text] [Related]
57. Impact of an altered Wnt1/β-catenin expression on clinicopathology and prognosis in clear cell renal cell carcinoma.
Kruck S; Eyrich C; Scharpf M; Sievert KD; Fend F; Stenzl A; Bedke J
Int J Mol Sci; 2013 May; 14(6):10944-57. PubMed ID: 23708097
[TBL] [Abstract][Full Text] [Related]
58. Aberrant expression of vasculogenic mimicry, PRRX1, and CIP2A in clear cell renal cell carcinoma and its clinicopathological significance.
Wang X; Yang R; Wang Q; Wang Y; Ci H; Wu S
Medicine (Baltimore); 2019 Sep; 98(36):e17028. PubMed ID: 31490389
[TBL] [Abstract][Full Text] [Related]
59. β1,6-N-acetylglucosaminyltransferase V predicts recurrence and survival of patients with clear-cell renal cell carcinoma after surgical resection.
Liu Y; Liu H; Liu W; Zhang W; An H; Xu J
World J Urol; 2015 Nov; 33(11):1791-9. PubMed ID: 25630622
[TBL] [Abstract][Full Text] [Related]
60. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
